27/01/2025
Dr. Matti Aapro, President, SPCC, Switzerland, joins OncoDaily at BGICC 2025 to discuss the use of CDK4/6 inhibitors in metastatic breast cancer. He shares insights from the SuFIA study, highlighting when hormone therapy alone may suffice before introducing CDK4/6 inhibitors. Tune in to explore personalized treatment strategies, cost considerations, and the potential role of these inhibitors in adjuvant settings.
Dr. Matti Aapro, President, SPCC, Switzerland, joins OncoDaily at BGICC 2025 to discuss the use of CDK4/6 inhibitors in metastatic breast cancer. He shares i...